Darren Foard

1.8k total citations
38 papers, 930 citations indexed

About

Darren Foard is a scholar working on Molecular Biology, Nephrology and Genetics. According to data from OpenAlex, Darren Foard has authored 38 papers receiving a total of 930 indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 19 papers in Nephrology and 11 papers in Genetics. Recurrent topics in Darren Foard's work include Amyloidosis: Diagnosis, Treatment, Outcomes (38 papers), Parathyroid Disorders and Treatments (18 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Darren Foard is often cited by papers focused on Amyloidosis: Diagnosis, Treatment, Outcomes (38 papers), Parathyroid Disorders and Treatments (18 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Darren Foard collaborates with scholars based in United Kingdom, United States and Italy. Darren Foard's co-authors include Ashutosh Wechalekar, Julian D. Gillmore, Philip N. Hawkins, Thirusha Lane, Lisa Rannigan, Helen J. Lachmann, Carol Whelan, Christopher P. Venner, Sajitha Sachchithanantham and Simon Gibbs and has published in prestigious journals such as Blood, Kidney International and European Respiratory Journal.

In The Last Decade

Darren Foard

35 papers receiving 916 citations

Peers

Darren Foard
Lisa Rannigan United Kingdom
Ray Comenzo United States
Kathleen T. Finn United States
Gabriele Sarais Italy
David Lavergne France
Mark Offer United Kingdom
James E. Hoffman United States
Steven R. Schuster United States
DV Faller United States
Xianghua Huang China
Lisa Rannigan United Kingdom
Darren Foard
Citations per year, relative to Darren Foard Darren Foard (= 1×) peers Lisa Rannigan

Countries citing papers authored by Darren Foard

Since Specialization
Citations

This map shows the geographic impact of Darren Foard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darren Foard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darren Foard more than expected).

Fields of papers citing papers by Darren Foard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darren Foard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darren Foard. The network helps show where Darren Foard may publish in the future.

Co-authorship network of co-authors of Darren Foard

This figure shows the co-authorship network connecting the top 25 collaborators of Darren Foard. A scholar is included among the top collaborators of Darren Foard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darren Foard. Darren Foard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khwaja, Jahanzaib, Sriram Ravichandran, Oliver C. Cohen, et al.. (2025). Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis. British Journal of Haematology. 206(4). 1141–1148. 1 indexed citations
2.
3.
Khwaja, Jahanzaib, Sriram Ravichandran, Darren Foard, et al.. (2024). Prognostication in IgM and Lymphoplasmacytic Lymphoma Associated Systemic AL Amyloidosis. Blood. 144(Supplement 1). 4684–4684.
4.
Khwaja, Jahanzaib, Sriram Ravichandran, Oliver Cohen, et al.. (2024). Refining prognostication in systemic AL amyloidosis: limited value of dFLC. Amyloid. 31(4). 353–355. 3 indexed citations
5.
Khwaja, Jahanzaib, Sriram Ravichandran, Oliver Cohen, et al.. (2023). Limited Utility of Mayo 2012 Cardiac Staging System for Risk Stratification of Patients with Advanced Cardiac AL Amyloidosis - Analysis of a Uniformly Treated Cohort of 1275 Patients. Blood. 142(Supplement 1). 537–537. 5 indexed citations
6.
Cohen, Oliver, Regina Rendas‐Baum, Kristen McCausland, et al.. (2023). Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light‐chain amyloidosis. British Journal of Haematology. 201(3). 422–431. 3 indexed citations
7.
Ravichandran, Sriram, Oliver Cohen, Steven Law, et al.. (2021). Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib. Blood Cancer Journal. 11(6). 118–118. 20 indexed citations
8.
9.
Rezk, Tamer, Helen J. Lachmann, Marianna Fontana, et al.. (2019). Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers. British Journal of Haematology. 186(3). 460–470. 15 indexed citations
10.
Rezk, Tamer, Andrew Davenport, Helen J. Lachmann, et al.. (2018). Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis. British Journal of Haematology. 185(5). 977–980. 4 indexed citations
11.
12.
Rezk, Tamer, Helen J. Lachmann, Marianna Fontana, et al.. (2017). Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor. Kidney International. 92(6). 1476–1483. 19 indexed citations
13.
Mahmood, Shameem, Sajitha Sachchithanantham, Thirusha Lane, et al.. (2016). Comparison of Free Light Chain Assays. American Journal of Clinical Pathology. 146(1). 78–85. 7 indexed citations
14.
Sachchithanantham, Sajitha, Mark Offer, Christopher P. Venner, et al.. (2015). Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis. Haematologica. 100(11). 1469–1476. 11 indexed citations
15.
Mahmood, Shameem, Leena George, Milind Sovani, et al.. (2014). High prevalence of sleep disordered breathing (SDB) in patients with systemic AL amyloidosis. European Respiratory Journal. 44(Suppl 58). P4928–P4928. 1 indexed citations
16.
Venner, Christopher P., Julian D. Gillmore, Sajitha Sachchithanantham, et al.. (2014). A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia. 28(12). 2304–2310. 64 indexed citations
17.
Wechalekar, Ashutosh, Stefan Schönland, Efstathios Kastritis, et al.. (2013). A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 121(17). 3420–3427. 334 indexed citations
18.
Sachchithanantham, Sajitha, Shameem Mahmood, Rabya Sayed, et al.. (2013). Biweekly Bortezomib Is More Efficacious Than Weekly Bortezomib When Used As First Line In Patients With Systemic AL Amyloidosis. Blood. 122(21). 1981–1981. 2 indexed citations
19.
Venner, Christopher P., Thirusha Lane, Darren Foard, et al.. (2012). Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 119(19). 4387–4390. 197 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lisa Rannigan Breakdown of academic impact, for papers by Ray Comenzo Breakdown of academic impact, for papers by Kathleen T. Finn Breakdown of academic impact, for papers by Gabriele Sarais Breakdown of academic impact, for papers by David Lavergne Breakdown of academic impact, for papers by Mark Offer Breakdown of academic impact, for papers by James E. Hoffman Breakdown of academic impact, for papers by Steven R. Schuster Breakdown of academic impact, for papers by DV Faller Breakdown of academic impact, for papers by Xianghua Huang
Rankless by CCL
2026